• Mechanism of action data shows how (E,E)-bisantrene silences MYC gene expression by stabilizing G-quadruplex structures
• Presentation supports Racura's current and planned clinical trials
• Strong interest and positive reception at the AACR conference

Racura Oncology (ASX: RAC) announced that its Senior Scientist, Dr Sumit Sahni, presented mechanism of action data on (E,E)-bisantrene at the 2026 American Association of Cancer Research (AACR) Annual Meeting. The data discloses results from preclinical studies demonstrating that (E,E)-bisantrene silences MYC gene expression by stabilizing a G-quadruplex (G4) DNA structure located in the promoter region of the c-MYC oncogene. The presentation titled '(E,E)-bisantrene silences c-MYC expression by stabilizing its promotor region G-quadruplex' showed that (E,E)-bisantrene binds to and stabilizes the G4 DNA structure in the c-MYC promoter, leading to silencing of the key cancer driver MYC. The data supports Racura's current and planned clinical trials of (E,E)-bisantrene, including Phase 1 trials in advanced solid tumors and EGFR-mutant non-small cell lung cancer. Racura's Senior Scientist commented that the strong interest and positive reception of this work at the prestigious AACR conference is very encouraging.